HealthJun 03, 2026
Apogee Therapeutics, Inc. raises $1.30B (Jun 2026)
$1.30B
$1.3BGenerated social card
Headline
APGE: Strong phase II-B results and a $1.3B Blackstone deal drive late-stage and combo program expansion - TradingView
About
Apogee Therapeutics, Inc. is focused on developing innovative therapies for atopic dermatitis and other conditions. The company is expanding its clinical trials into asthma and eosinophilic esophagitis (EoE), supported by a significant funding deal with Blackstone.
Article summary
APGE: Strong phase II-B results and a $1.3B Blackstone deal drive late-stage and combo program expansion TradingView
Investors · 1
BlackstoneLead
FUND
Related rounds
| Jun 04, 2026 | Novellia | $18.0M | Series A | United States |
| Jun 03, 2026 | CrossBridge Bio | $300.0M | — | United States |
| Jun 03, 2026 | NewLimit | $435.0M | Series C | United States |
| Jun 01, 2026 | $14.0M | — | — |